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ABSTRACT
Characterization of a 30S Ribosomal Subunit Assembly Intermediate Found in
Escherichia coli Cells Growing with Neomycin or Paromomycin
by
Cerrone Renee Foster
The bacterial ribosome is a target for inhibition by numerous antibiotics.
Neomycin and paromomycin are aminoglycoside antibiotics that specifically
stimulate the misreading of mRNA by binding to the decoding site of 16S rRNA in
the 30S ribosomal subunit. Recent work has shown that both antibiotics also
inhibit 30S subunit assembly in Escherichia coli and Staphylococcus aureus
cells. This work describes the characteristics of an assembly intermediate
produced in E.coli cells grown with neomycin or paromomycin. Antibiotic
treatment stimulated the accumulation of a 30S assembly precursor with a
sedimentation coefficient of 21S. The particle was able to bind radio labeled
antibiotics both in vivo and in vitro. Hybridization experiments showed that the
21S precursor particle contained 16S and 17S rRNA. Ten 30S ribosomal
proteins were found in the precursor after inhibition by each drug in vivo. In
addition, cell free reconstitution assays generated a 21S particle during
incubation with either aminoglycoside. Precursor formation was inhibited with
increasing drug concentration. This work examines features of a novel antibiotic
target for aminoglycoside and will provide information that is needed for the
design of more effective antimicrobial agents.
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CHAPTER 1
INTRODUCTION
Antimicrobial Resistance
The increasing emergence of bacterial strains resistant to antimicrobial
agents has been a persistent medical challenge for decades and is recognized
as a grave public health problem. For many microorganisms second and third
generation antibiotics are becoming less effective in treating infection and for
others a single antibiotic is the only treatment available. Thus, the discovery of
novel compounds to counter resistance remains one of the most important goals
for medical research (Anderson 1999).
The design of more effective antimicrobial agents has focused on
modifying existing drugs that rely on the same molecular targets (Knowles 1997).
It has been the goal of pharmaceutical companies over the past decades to
design compounds that combat resistance mechanisms. Since the discovery of
penicillin in the 1940s, companies have been continuously improving antibiotic
effectiveness by manufacturing second, third, and fourth generation
antimicrobials. This effort to modify existing compounds began 20 years after the
discovery of penicillin. Yet, by the 1980s almost 80% of Staphylococcus aureus
isolates had become resistant to penicillin. By 2002, more than 57% of S. aureus
isolates were resistant to the new classes of antibiotics, leaving the cell wall
inhibitor vancomycin, as the last drug of choice (Mills 2006). Eventually,
vancomycin resistant strains emerged and the lipopeptide antibiotic daptomycin
13

was the next compound of choice. Not surprisingly, within a year of FDA approval
daptomycin resistant strains emerged (Mangili and others 2005).
A resolution to this problem now focuses on identifying new targets that
inhibit essential bacterial functions (Chu and others 1996). However, this has not
been a straightforward task. In the past 20 years there has been a decrease in
the number of FDA approved drugs and of the 10 approved since 1998, only
daptomycin has a novel drug site. And this was only 43 years following its
discovery (Spellberg and others 2004; Norrby and others 2005).
It is very clear that identifying new drug targets should be of foremost
priority. The targets with the greatest potential have been defined by their
biological importance. Therefore, examining universal and essential cellular
functions would be of utmost significance (Lerner and Beutel 2002). Protein
biosynthesis is a fundamental cellular process and is a well-characterized
antibacterial target. A number of antibiotic classes function by interacting with the
fully formed 50S or 30S ribosomal subunits. However, resistance mechanisms
that modify ribosomal RNA sequences in the fully formed subunits have
compromised the utility of these compounds (Shaw and others 1998; Beauclerk
and Cundliffe 1987). On the other hand, little attention has been given to the
formation of these subunits, which also happens to be an important cellular
process (Champney 2006). Accurate assembly of ribosomes is undeniably
essential to the bacterial cell. For this reason, drugs preventing bacterial
ribosome assembly may be a more fundamental target.
14

30S Subunit Structure and Function
The bacterial ribosome is a large macromolecular complex whose primary
task is deciphering the genetic code and stimulating peptide bond formation. This
is accomplished by both the 30S and 50S subunits. The small subunit sediments
at 30S and binds mRNA, initiation factors, and the large subunit. It also
participates in tRNA selection, thus playing a critical role in translational fidelity.
The large subunit sediments at 50S and is responsible for peptide bond
formation and movement of the ribosome along the mRNA sequence (Noller
1991).
Resolution of the crystal structure has provided insight into the 30S subunit
architecture. About two-thirds of the subunit is RNA and the remaining one-third
is ribosomal proteins. The secondary structure (Figure 1A) consists of four
domains that organize into the structural regions shown in Figure 1B denoted as
the head, body, shoulder, and the platform. The 5' rRNA domain forms the body
and the central domain establishes the platform. The 3' minor and major
domains assemble into the head and shoulder regions respectively (Wimberly
and others 2000). Although non-functional, each of the 16S RNA domains can
assemble separately (Nierhaus 1991; Powers and others 1993; Weitzman and
others 1993). These four domains are connected by a region known as the neck,
which is critical for the final 30S conformation and function (Wimberly and others
2001).
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A.

B.

Figure 1 Secondary and Three Dimensional Structures of E.Coli 16S rRNA and
30S Subunit. A.) Secondary structure of 16S rRNA domains. The central, 3'
major and minor, and 5' domains are colored; red, blue, purple, and green
respectively. The 16S rRNA region enclosed by brackets represents the
decoding region. B.) 3D structure of the 30S subunit. The head, platform,
penultimate stem, and body are formed by the RNA domains shown in A and the
decoding center is shown by the arrow (adapted from Holmes and Culver 2004).
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Ribosomal Protein Structure
While mainly composed of RNA, the significance of ribosomal proteins to
30S function must not be underestimated. Both by direct and indirect
interactions, ribosomal proteins are paramount to the organization of the subunit
and RNA catalytic activity of the subunit depends on protein association. For
example, direct binding of ribosomal proteins assist in domain assembly by
initiating the tertiary fold between RNA helical junctions (Brodersen and Ditlev
2005). In addition, direct contacts with long protein extensions help stabilize the
final structure. These extensions are highly basic thereby neutralizing the
negatively charged RNA backbone. These narrow extensions are able to make
direct and specific contacts with the RNA, anchoring the protein deep within the
RNA folds. On the other hand, hydrophobic protein-protein interactions stabilize
the structure indirectly by docking between RNA domains (Brodersen and Ditlev
2005). Overall, ribosomal proteins assist in domain organization to create
functional binding centers.
The decoding center on the 30S subunit is the binding site for
aminoglycoside antibiotics. Located between the head and the body, it is
primarily composed of RNA. It is joined by helix 44 in the 3' minor domain with
loop 530, and projections of 4 ribosomal proteins (Moore and Steitz 2002).
Some of the current work on 30S structure and function involves characterizing
the interactions of 16S rRNA with aminoglycoside antibiotics within this site.
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Structure of Aminoglycosides
Isolated from Streptomyces fradiae in 1949, neomycin and paromomycin
are two of several aminoglycosides that bind to the decoding center. They are
effective against a number of aerobic and facultative anaerobic microorganisms
(Kotra and others 2000). This makes them useful in treating abdominal and
urinary tract infections and preventing endocarditis and bactermia. In most
instances, these antibiotics are fast acting bactericidal agents and are
synergistically effective against nosocomial infections (Jana and Deb 2006).
The aminoglycosides are four member-ring compounds composed of a 2deoxystreptamine linked to several amino sugars. The positions of the linkages
distinguish the different aminoglycoside classes. The 4,5 disubstituted class
consists of neomycin and paromomycin. As shown in Figure 2, paromomycin
and neomycin differ in chemical structure by the functional group attached to the
C'6 of ring 1. Paromomycin has a hydroxyl group at this position, while neomycin
possesses an amino group (Benveniste and Davies 1973, Schroder and Wallis
2001). These RNA binding antibiotics have several features that contribute to
their antimicrobial activity. Their high positive charge enhances their attraction
to the negatively charged RNA backbone. In addition, these features also permit
promiscuous interactions with several other types of RNA motifs (reviewed in Tor
2006).
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Figure 2 Structure of Neomycin and Paromomycin. Neomycin has an amino
group and paromomycin has a hydroxyl group (indicated by the arrow).

Figure 3 shows paromomycin complexed to the ribosomal A site. Rings I
and II mediate the direct and specific interactions of the antibiotic with the A site.
The drug binds to the major groove within an RNA pocket created by bases
A1408, A1492, and A1493. Ring I forms a pseudo base pair with A1408 and
stacks above C1409:G1491. The amino groups at positions 1 and 3 shown in
Figure 3 serve as hydrogen bond donors to U1495 and G1494. The amino
groups at positions 1 and 3 of ring II are also essential for binding to the
decoding site of 16S rRNA. This binding induces a conformational change, that
facilitates additional binding of the antibiotic to the rRNA (Fourmy and others
1996,1998; Recht and others 1999). This same interaction is found with other
distinct classes of aminoglycosides and explains the general specificity of the
19

neamine core for the A site (Blanchard and others 1998). Rings III and IV are
accommodated into the major groove toward the lower stem of the A site.
Although these rings do not make base specific contacts with the RNA, they
contribute to the specificity by providing additional positive charges (Schroeder
and Wallis 2001).

Figure 3 Structure of Paromomycin Complexed to the Ribosomal A Site.
Paromomycin complexed to the A site is shown in stereo view. Rings I and II of
paromomycin make base specific contacts with A1408, U1495, G1494, A1493,
and G1491. Rings III and IV do not interact within the RNA pocket but contribute
the antibiotics induced fit. The blue represents the RNA backbone and tan
represents paromomycin. The dashed lines represent possible hydrogen bonds
(adapted from Schroeder and Wallis 2001).
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A detailed examination of aminoglycosides and A site interactions
concluded that the 16S rRNA sequences within the decoding region were
sufficient to elicit a conformational change in structure (Fourmy and others 1998).
Footprinting experiments (Recht and others 1999) using an E.coli 16S rRNA 27mer oligonucleotide identified the nucleotides that were critical for high affinity
paromomycin binding. Subsequently, NMR studies revealed that drug binding to
these nucleotides produced a change in the conformation of the decoding region
of the 30S subunit (Lynch and Puglisi 2001) (Figure 4).

A

B

Figure 4 Paromomycin Complexed With the A Site Induces a Conformational
Change. A.) Nucleotides of the ribosomal A site that are involved in
paromomycin binding. The triangles represent bases protected from
dimethylsulfate modification in the presence of antibiotic. B.) Binding of
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paromomycin results in the “flipping out” of A1492 and A1493 (adapted from
Pfister and others 2005).
Inhibition of Translation
Neomycin and paromomycin are specific for the 30S subunit and induce
misreading of the genetic code and mistranslation of messenger RNA (Davies
and others 1965,1968). In the absence of the antibiotics, translation begins with
initial selection of an amino acyl-tRNA (cognate) through mRNA base paring.
Recent structural data has shown that base pairing alone is not sufficient to
ensure translational fidelity. Instead, the proofreading capacity depends on a
highly energetic conformational change that is a prerequisite for cognate tRNA
binding. Aminoglycosides bypass this discriminatory step facilitating a change in
structure that allows non-cognate tRNA binding with high affinity (Figure 5). As a
result, the error frequency is increased (Ogle and others 2001,2002,2003).
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Aminoglycoside

Figure 5 Conformational Dynamics of the Decoding Site During tRNA Selection
and Antibiotic Binding. A.) A1492 and A1493 are in conformational equilibria
between the “flipped in” or flipped out states, with the intrahelical states being
favored in the absence of drug. In their extrahelical states, A1492 and A1493
are able to interact with the tRNA anticodon (magenta) and the mRNA codon
(blue). This interaction being favored in the presence of the cognate tRNA
anticodon and disfavored in the presence of a non-cognate tRNA anticodon. B.)
The effects of aminoglycoside binding to the decoding region. The drug (shown
in brown) binds to the 16S rRNA and shifts the conformational equilibria of A1492
and A1493 toward their “flipped out” states. As a result, A1492 and A1493 are
now able to engage in favorable interactions with the codon-anticodon minihelix,
even when the anticodon is non-cognate (adapted from Pilch and others 2005).
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Ribosome Assembly
Rearrangement of the 30S subunit by a molecule less than 1000 times its
molecular weight has revolutionized current understanding of ribosome structure
and function. More than 40 years of investigation on this massive structure have
revealed details of interactions within the fully formed particle as well as its
subunits. In contrast, details of how ribosomal subunits are assembled still
remain elusive (Culver 2003).
Several in vitro techniques have been employed to characterize the
assembly pathway of the 30S subunit (Nomura 1973, Stern and others 1989).
Ribonuclease cleavage and proteolytic digestion has been used to identify
elements of 16S rRNA that interact with proteins (Powers and Noller 1995).
Ribosomal reconstitution and protection experiments have been performed to
examine protein dependent RNA rearrangements that occur to form the 30S
subunit (Traub and Nomura 1968; Nashimoto and others 1971; Powers and
others 1993). Altogether, these data revealed that assembly is a multistep
cooperative process coupled with RNA transcription in cells.
The precursor 16S RNA transcript results from cleavage of a larger
precursor RNA by ribonuclease III. This results in an immature 16S sequence
with a 115 nt and 33 nt extension at the 5' and 3' ends respectively. While RNA
maturation is coupled with the addition of ribosomal proteins, the precursor
sequences may help to promote a conformation required for subunit assembly
24

(Nicholson 1999; Deutscher 2003). During the initial stage, major RNA
rearrangements occur forming many of the protein binding sites. This would
include sites for primary binding proteins shown in Figure 6A. As assembly
proceeds, major changes in protection occur in the 5' domain, then shifting to the
3' domain. This is consistent with data revealing a subset of protein dependent
protections in the 5' and central domains in the 21S intermediate (Figure 6B).
The addition of tertiary binding proteins results in structural rearrangements with
protected nucleotides in the 3' minor and major domains, a pattern consistent
with mature 30S subunits (Holmes and Culver 2004, 2005).

25

A.

BODY

PLATFORM

HEAD

B.

Figure 6 5' to 3' Polarity of Ribosomal Protein Binding to 16S RNA. A.) The
primary binding proteins shown in black bind to the 5' and central domain during
the early stages of assembly. Proteins shown in green are also primary binding
proteins but associate midway during assembly. The tertiary domains that are
formed by each protein is also shown. B.) Secondary proteins that bind to the 5'
and central domain are shown in pink (adapted from Culver 2003).
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These data revealed that three major transitions in RNA structure take
place during subunit formation. First, initial binding of primary proteins nucleate
assembly and the subsequent addition of secondary proteins produces a 21S
intermediate (RI). Shown in Figure 7 is a possible structural arrangement of this
particle and its proteins. In vitro reconstitution assays revealed that the second
RNA conformational change is solely energy dependent and does not require
additional protein binding. This particle sediments at 26S and is critical in
forming the additional binding sites for the tertiary ribosomal proteins (Mizushima
and others 1970; Held and others 1973,1974). Figure 8 is a 30S assembly map
that shows the interdependencies of protein binding for 30S subunit formation.

27

A

Figure 7 Schematic Representation of the 21S Ribosomal Intermediate. A
representation of the structural arrangement of the in vitro 21S ribosomal
intermediate (RI). This structure was prepared using the x-ray data of Wimberly
and others (2000) for the Thermus thermophilus 30S ribosome to 3A resolution
(PDB Id 1J5E). The neomycin and paromomycin binding site is indicated by A.
No tertiary proteins are shown in this particle (adapted from Holmes and Culver
2005)
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1°

2°

3°

Figure 8 Representation of 30S Subunit Protein Assembly Map. Primary binding
proteins are shown in the first row. Secondary and tertiary proteins are shown in
second and third row respectively. The arrows represent the interdependence of
each protein. Proteins in red, green, and blue bind to the 5', central, and 3'
domains respectively (adapted from Culver 2003).
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Previous Studies
Collectively these results suggest that a subset of proteins are critical for
30S subunit formation and their cooperative role is to facilitate the conformational
changes in 16S rRNA to form a functional subunit. How this process is impaired
by aminoglycosides and what 16S rRNA conformational change is needed to
bind these antibiotics remains unclear (Culver 2003; Champney 2006).
Recently, the work of Mehta and Champney revealed that
aminoglycosides have a second inhibitory target on the 30S subunit. These
results were prompted by the work of previous investigations showing that a
number of compounds that inhibit translation also prevent ribosome assembly in
growing cells (Mehta and Champney 2002, 2003). The macrolides, ketolides,
lincosamides, and streptogramin B compounds prevent assembly of the 50S
subunit with little or no effect on the small subunit (Champney 2003). Inhibition
by the macrolide antibiotic erythromycin produced an intermediate particle that
sedimented in the 30S region of a sucrose gradient. Gel electrophoresis
revealed that the assembly intermediate was composed of 23S and 5S ribosomal
RNA from the large subunit, as well as 18 of the 34 ribosomal proteins (Usary
and Champney 2001). It has been shown in both E. coli and S.aureus, that
neomycin and paromomycin inhibit 30S ribosomal subunit assembly in growing
cells in a similar manner to 50S inhibition, producing a 21S assembly
intermediate. It was shown that these antibiotics are specific for 30S assembly,
with little or no effect on 50S assembly (Mehta and Champney 2002, 2003). This
30

work was the first identification that aminoglycosides inhibit 30S subunit
assembly in vivo. Unlike the 50S assembly intermediate, the 21S precursor
(p30S) remains uncharacterized.
The model for assembly inhibition in Figure 9 proposes that in the
absence of antibiotic, assembly proceeds normally forming a functional subunit
with a binding site (A). In the presence of neomycin or paromomycin at the IC50,
half of the cells go on to form functional subunits that can be inhibited in
translation (Figure 9B) and the other half are inhibited during assembly. It
remains unclear whether these pathways are identical. Last, the intermediate
would be degraded by cellular ribonucleases in a similar manner as the large
subunit (Silvers and Champney, 2005).
This work is intended to explore the observation that many antibiotics that
inhibit the translational functions of the bacterial ribosome also prevent its
assembly in microbial cells. 30S assembly inhibition by neomycin and
paromomycin has been examined in vivo by characterizing the rRNA and protein
composition of the precursor particle.

31

Figure 9 Model of 30S Subunit Assembly in E.coli Cells. A.) The pathway of
normal 30S assembly. B.) In the presence of the aminoglycoside, subunit
assembly stalls and an assembly intermediate accumulates with the drug bound
in a site (I) similar to the site found on the mature 30S subunit (A). Cellular
ribonucleases degrade the intermediate into rRNA oligonucleotides and free
ribosomal proteins (adapted from Usary and Champney 2001).
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CHAPTER 2
MATERIALS AND METHODS
Media
Tryptic Soy Broth: 30 g tryptic soy broth in 1 L dH2O.
Minimal Media: 100 ml 1X A-salts, 1 ml 20% glucose, 0.1 ml 20% MgSO4, and
0.05 ml thiamin [1mg/ml].
5X A-salts: 52.5 g K2HPO4, 22.5 g KH2PO4, 5 g (NH4) 2SO4, and 2.5 g Na
citrate×(2H2O) to 1 L with dH2O.

Buffers
S-Buffer: 10 mM Tris-HCl (pH 8.0), 50 mM NH4Cl and 0.5 mM Mg Acetate.
R-Buffer: 10 mM Tris-HCl (pH 8.0), 50 mM NH4Cl, 10 mM Mg Acetate, and 0.2
mM β-mercaptoethanol.
Ribosome Wash: 10% sucrose, 2M NH4Cl, 10 mM MgCl2, 10 mM Tris-HCl
(pH 8.0)
Binding Buffer: 50 mM Tris-HCl (pH 7.8), 80 mM KCl, 16 mM Mg Acetate
Wash Buffer: 25 mM Tris-HCl (pH 7.8), 60 mM KCl, 20 mM Mg Acetate
10X MOPS Buffer: 0.2 M MOPS (pH 7.0), 20 mM sodium acetate, 10 mM EDTA
(pH 8.0).
RNA Resuspension Buffer: 150 µl formamide, 36 µl formaldehyde, 30 µl 10X
MOPS buffer.
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RNA Running Buffer: 900 ml sterile dH2O, 100 ml 10X MOPS buffer.
Alkaline Transfer Buffer: 3 M NaCl, 8 mM NaOH, and 2 mM Sarkosyl.
5X Neutralizing Buffer: 0.5M Na2HPO4, 0.5M NaH2PO4 in 1 L dH2O
Formamide Hybridization Buffer: 50% formamide, 5X SSC, 0.1 % sarkosyl,
0.02% SDS, 200 µg/ml BSA, with 1X background quencher.
TE buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA.
20X SSC: 3.0 M NaCl, 0.3 M Na citrate and HCl to adjust pH to 7.0.

Protein Electrophoresis Buffers
1st dimension sample buffer: 0.01 M Bis-Tris (pH 4.2), 7.6 M urea, 6mM acetic
acid, 0.14 M β-mercaptoethanol in 10 ml dH2O.
1st dimension upper tank buffer: 0.01M Bis-Tris (pH 3.8) and 3.6 mM acetic acid
in 1 L dH2O.
1st dimension lower tank buffer: 0.01 M Bis-Tris (pH 6.0) and 0.4 mM acetic acid
in 1 L dH2O.
1st dimension separating gel solution: 0.4 M Bis-Tris (pH 5.5), 0.45 mM acetic
acid, 4% acrylamide, 0.66% bis-acrylamide and 8M urea.
2nd dimension separating gel solution: 0.44M glacial acetic acid (pH 4.5), 0.44M
KOH, 18% acrylamide, 0.5% bis-acrylamide and 6M urea.
2nd dimension running buffer: 0.93M glacial acetic acid (pH 4.0) and 0.93M
glycine.
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Reconstitution Buffers
Buffer #4: 20 mM Tris-HCl (pH 6.0), 4 mM Mg acetate, 400 mM NH4Cl, 0.2 mM
EDTA and 5 mM β-mercaptoethanol.
Buffer #5: 20 mM Tris-HCl (pH 6.0), 4 mM Mg acetate, 400 mM NH4Cl, 0.2 mM
EDTA, 5 mM β-mercaptoethanol, and 6M urea
Buffer #7: 10 mM Tris-HCl (pH 7.6) and 4 mM Mg acetate.
Buffer # 9: 110 mM Tris-HCl (pH 8.0), 4 mM Mg acetate, 4 M NH4Cl, 0.2 mM
EDTA and 20 mM β-mercaptoethanol.
Bacterial Cell Growth
Escherichia coli ribonuclease deficient strain D10-1, an RNase I mutant
(Gesteland 1966), and SK901 (Mehta and Champney 2002) were used in this
study. Cells were grown in either tryptic soy broth or minimal media (A salts and
0.2% glucose) (Miller 1972). Fresh media was inoculated with an overnight
bacterial culture. The growth rate was measured by following the increase in cell
density in a Klett Summerson calorimeter at 27°C. Neomycin, paromomycin, and
streptomycin were added at a cell density of 15 Klett units. The cells were
harvested after two cell doublings (60 Klett units).
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Analysis of Ribosomal RNA
Primer Design
A 101 nt 16S DNA probe was generated by amplifying a region of 16S
DNA from plasmid pKK3535 using the polymerase chain reaction. PCR reaction
mixtures contained 45μl of PCR Supermix High Fidelity reagent (Gibco BRL), 1μl
of plasmid DNA (6.5ng), 1μl (10 pmol) of 16S forward and reverse primers, and
2μl of sterile water. The forward primer was: GGAGGAAGGTGGGGATGACG
and the reverse primer was ATGGTGACGGGCGGTGTG (nt. no. 1173-1414)
from Life Technologies. Samples were amplified for 35 cycles under the
following conditions: denaturation at 94°C for 30 sec, annealing at 57°C for 30
sec, and extension at 72°C for 30 sec. The PCR product was purified by
extraction with an equal volume of phenol and chloroform and precipitated with 2
volumes of ethanol. Single stranded DNA probes for 16S rRNA precursor
sequences were purchased from One Trick Pony Corporation. The sequence for
the 5' precursor is: 5'-CGC TCA AAG AAT TAA ACT TCG-3' and the 3' precursor
is: 5'- ACG CTT CTT TAA GGT AAG G-3' (Figure 10). The PCR product and
precursor probes were resuspended in sterile water and labeled with biotin using
the Label-IT biotin labeling kit (Mirus).
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5'UGUGUGGGCACTCGAAGAUACGGAUUCUUAACGUCGCAAGACGAAAAAUGAAUACCGAAGUCUCAAG
AGUGAACACGUAAUUCAUUACGAAGUUUAAUUCUUUGAGCGUCAAACUUUUAAAUUGAAGAGUUUGA
UCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUCGAACGGUAACAGGAAGAAGC

16S MATURE SEQUENCE
CUGGGGUGAAGUCGUAACAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACCUCCUUACCUUAAAGA
AGCGUACUUUGUAGUGCUCACACAGAUUGUCU 3'

Figure 10 Upstream and Downstream Regions of 16S RNA Sequence.
Nucleotides in red represent the probes for the precursor region. The 5' probe
begins +10 nt upstream of the mature sequence. The 3' probe overlaps with the
last four nucleotides of the mature sequence.
Slot Blot Hybridization
E. coli cells were harvested after two cell doublings by centrifugation in a
Beckman centrifuge (J2-21) at 6,000 rpm for 12 minutes in a JA21 rotor. Cell
pellets were washed with sterile S-buffer. Washed pellets were centrifuged again
at 6,000 rpm for 12 minutes. The cell pellets were stored at -70°C before cell
lysis.
Cells were lysed with lysozyme by the freeze thaw method. Washed cell
pellets were thawed at room temperature and resuspended in 200 µl of S- buffer
and 15 µl of a 5 mg/ml solution of lysozyme was added. Cells were allowed to
incubate at room temperature for 15 to 20 minutes and were then subject to a
freeze-thaw process. Cells were frozen for 5 minutes at -70°C and then thawed
at room temperature. This procedure was repeated twice. DNA was digested in
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cell lysates by adding 2 units of DNAase I to each sample. The samples were
centrifuged at 6,000 rpm for 12 minutes.
Cells lysates were added to 5-20% sucrose gradients and spun at 39,000K
for 5.5 hrs in a SW40 rotor. RNA for slot blot hybridization was prepared from
sucrose gradient fractions. Any DNA that would present contamination for the
slot blot analysis would have been separated on the gradient and not present in
30S and 50S subunit fractions. Each fraction from the sucrose gradient was
digested with 10 μg of proteinase K (Fluka) in 0.1 % SDS for 2 hours at 44°C
followed by ethanol precipitation (2 volumes) and resuspended in 0.2 mL of
dH2O.

RNA from each fraction was applied to a nylon membrane (Nytran) using

a slot blot apparatus. The membranes were washed with 0.5 mL of TE buffer and
RNA was cross linked using a UV oven. The membranes were placed in 50 ml
plastic corex tubes with 15 ml of 1X pre-hybridization solution (MRC, Inc.) and
allowed to incubate at 42°C for 30 minutes in a hybridization incubator (FisherBiotech). The pre-hybridization buffer was discarded and the membranes were
hybridized with the biotinylated 16S DNA probe overnight at 42°C with 4 pmol of
denatured 16S probe in 7 ml of hybridization buffer and 1X background quencher
(MRC Inc.). The probe was denatured by mixing with 0.1 volume of Mirus
Denaturation Buffer D1 and incubating at room temperature for 5 minutes. The
solution was chilled on ice and mixed with 0.1 volume of Mirus Neutralization
Buffer N1 and incubated at room temperature for 5 minutes.
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The probe was detected using the North to South Chemiluminescent
Detection Kit (Pierce) using a horseradish peroxidase strepavidin conjugate for
biotin detection. The membrane was covered with plastic wrap on a glass plate
and exposed to Fuji Medical X-ray film. X-ray film was developed by soaking the
film in Kodak GBX developer for 1-5 minutes, rinsing in H2O, soaking in fixer and
replenisher for 1-5 minutes, followed with a final rinsing in H2O. The average
spot intensity for each fraction was quantified by scanning the film using an Alpha
Innotech image analysis system.
Northern Blot Analysis
Total RNA was isolated from E. coli cells using the Aqua Pure (Bio-Rad)
RNA isolation kit. Total RNA (5 μg) from cells treated with or without antibiotic
was denatured by heating at 55°C for 15 min and electrophoresed on a 1.8%
agarose gel for 2.5 hours (Farrell 1993). RNA was detected by Northern blot
analysis. The RNA was blotted onto nylon membranes using a Turboblot
apparatus. RNA transfer was performed using an alkaline transfer buffer for 2
hours. After the transfer, gels were checked for RNA by ethidium bromide
staining. The membrane was neutralized in 1X neutralizing buffer and the RNA
was cross-linked to the membranes using a UV oven (Fisher-Biotech).
Hybridization was performed as described for the slot blot experiment except the
membranes were hybridized separately for 20 hrs with the 5', 3', and 16S probes
at 32°C with hybridization buffer. The membranes were then washed in 6X SSC
for 15 min. The second stringency wash contained 0.1X SSC and 0.5% SDS for
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15 min at 50°C. Hybridization and stringency wash temperatures were performed
at 42°C for the 16S probe. The North to South Chemiluminesent Kit was used
for probe detection as previously described.
Two-Dimensional Polyacrylamide Gel Electrophoresis
Cells were grown in A salts minimal media (100 ml) with 35S-methionine
(5µCi/ml) and supplemented with 0.4 μg/ml of 19 amino acids excluding
methionine. Radio labeled cell lysates were spun through 5-20% R buffer
sucrose gradients as previously described for RNA analysis. Fractions containing
the precursor region and 30S subunits were collected and pooled. To detect any
contamination, the pooled region was respun on a sucrose gradient and the
precursor region was collected. Non-radio labeled 30S subunits (100μg) were
added to the pooled fractions as a carrier. Total ribosomal proteins were isolated
by treating subunits with 0.1 volume of 1M Mg Acetate and 2.2 volumes of glacial
acetic acid for 45 min at -20°C to extract the RNA. Next samples were spun at
10,000 rpm for 30 min. The RNA pellet was discarded and the ribosomal proteins
were precipitated from the supernatant with 5 volumes of acetone for 3 hrs at
4°C. Following centrifugation at 10,000 rpm for 30 min, the pellet was dried and
resuspended in sample buffer. The labeled proteins separated by twodimensional gel electrophoresis as previously described (Geyl and others 1981;
Usary and Champney 2001) the proteins were detected by Comassie Blue
staining. The protein spots were excised from the gel, digested with 0.5 ml 30%
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hydrogen peroxide at 85°C for 3 hrs and the amount of radioactivity was
determined by liquid scintillation counting. Data were normalized by dividing by
the number of methionine residues for each protein (Giri and others 1984).
Aminoglycoside Radio Labeling
Neomycin and paromomycin were radio labeled by reductive methylation
with 3H-formalydehyde as previously described (Champney 1989). During the
reductive methylation process protons on the amino groups of the
aminoglycoside were replaced with tritiated methyl groups from the 3HCOH.
Antibiotics were incubated at 37°C for 30 minutes under the following conditions:
neomycin and paromomycin (100μg), 3H formaldehyde (20nmol), NaCNBH3
(20µg), and 10mM NaPO4 buffer pH 6.6. The labeled antibiotic was separated
from free formaldehyde by chromatography on a Bio-Gel P2 column in 0.1M NH4
acetate buffer. Fractions containing the labeled drug were pooled, lyophilized and
resuspended in 200 μl of water. The specific activity for 3H-neomycin and 3Hparomomycin was 3.3mCi/mol, which was determined by measuring 2μl of the
sample by liquid scintillation counting.
Thin layer chromatography was performed to determine the number of
methylated amino groups (Roets and others 1995). Paromomycin and neomycin
(labeled and unlabeled) were dissolved in water at a concentration of 4.0 mg/ml
and 1.0 µl of each sample was applied to a cellulose TLC plate. The mobile
phase solution consisted of methanol-20% sodium chloride (vol/volume) (15:85).
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The mobile phase solution was equilibrated for at least 1 hour before use and the
mobile phase ascended over 12 cm in 2 hours. The plate was dried and
fluorography was performed by adding scintillator solution consisting of 7%
(weight/volume) solution of 2,5-diphenyloxalazole (scintillation grade) in ethanol
that was poured over the chromatograph as described (Toutchstone and Dobbins
1983). The chromatograph was used to expose x-ray film at -70°C for 2 days.
Figure 11 shows the autoradiograph of the labeled neomycin and paromomycin.
In addition to radio labeling, 3H-paromomycin was also purchased from Moravek
Biochemicals (0.6 Ci/mmol)
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Figure 11 Identification of Radiolabeled NH3 Groups of 3H-Paromomycin and 3HNeomycin. A.) Radioactive profile of fractions collected from a Bio Gel P2
column containing 3H-paromomycin. The smaller peak represents radio labeled
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antibiotic and the larger free 3H-formaldehyde. B.) Thin layer chromatography of
aminoglycosides prepared by reductive methylation. P represents 3Hparomomycin and N, 3H-neomycin.
In Vivo Binding Assay
E.coli cells were grown in minimal media in the presence of 3H-neomycin
or 3H-paromomycin (0.5μCi/ml) 6µg/ml, and streptomycin at 2µg/ml. The
antibiotics were added to cells at a Klett of 20, corresponding to 1.6 x 108
cells/ml. The cells were grown for two cell doublings and immediately harvested
and lysed by the freeze thaw method as described above. Cell lysates were spun
through 5-20% S buffer sucrose gradients for 5.5 hrs at 39,000 rpm in a SW40
rotor. Fractions were collected using an ISCO UV absorbance monitor and the
amount of 3H-antibiotic binding was measured by liquid scintillation counting.
In Vitro Binding Assay
30S, 50S, and p30S particles were isolated from sucrose gradients of cell
lysates as described for protein analysis. Subunits and precursors were pelleted
in a Ti50 rotor at 45,000 rpm for 16 hrs. The 21S precursor particle was dialyzed
against 100 ml of R buffer to remove bound antibiotic. Increasing amounts of 3Hparomomycin (Moravek Biochemicals) were incubated with 5 pmoles of p30S,
30S, or 50S in binding buffer at 37°C for 15 minutes. Particles with bound
antibiotic were captured on a 0.45 μm Millipore filter and washed with 10mL of
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wash buffer. Bound 3H-paromomycin was detected by liquid scintillation
counting.
Ribosomal Subunit Reconstitution
Isolation of RNA and Proteins
Ribosomal RNA was isolated from 30S subunits. These subunits were
from sucrose gradient lysates that were pelleted at 45,000 rpm for 18 hrs in a
Ti50 rotor. The pellets were resuspended in 1 ml of R buffer. The RNA was
extracted using 0.1 volumes of 10% SDS and 1.2 volumes of phenol. The
mixture was vortexed for 8 min and spun at 10,000 rpm for 10 min. Two volumes
of ethanol was added to the aqueous phase to precipitate RNA. After 2 hrs at
- 20°C the RNA was pelleted by centrifugation at 9,000 RPM for 45 min and
resuspended in buffer #7.
Total ribosomal proteins were isolated from 30S subunits by adding 0.1
volume of 1M Mg Acetate and 2.2 volumes of glacial acetic acid for 45 min at 20 ° C, followed by centrifugation at 10,000 rpm for 30 min. The RNA pellet was
discarded and the ribosomal proteins were precipitated from the supernatant by
adding 5 volumes of acetone for 3 hrs at 4°C. Following centrifugation at 10,000
rpm for 30 min, the pellet was dried and resuspended in 1 ml of buffer #5. The
proteins were dialyzed for 2 hrs against 100 ml of buffer #4.
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30S Subunit Reconstitution
Reconstitution was performed as previously described (Spedding 1990).
3

H-16S rRNA was isolated from cells grown with 1μg/ml 3H-uridine. In order to

halt further isotope incorporation after two cell doublings, uridine (50 µg/ml) was
added in excess to each culture. After a 15 min chase period, 3H-30S subunits
were isolated from sucrose gradients and the 3H-16S rRNA was extracted as
described above. Then 22 μg of 3H-16S rRNA and 200μg of total 30S ribosomal
proteins were incubated at 40°C in buffer # 9 for 20 min and immediately added
to ice. To examine assembly inhibition in vitro, neomycin and paromomycin were
added to the reconstitution mixture at final concentrations of 0.04, 0.2, and
0.4µM. Mixtures were then layered on 5 to 20% reconstitution buffer sucrose
gradients and centrifuged at 39,000 rpm for 5.5 hr in a SW40 rotor. Gradient
fractions were collected and counted by liquid scintillation.
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CHAPTER 3
RESULTS
Inhibition of Bacterial Cell Growth
E.coli cells were grown at 10μg/ml of neomycin or paromomycin, which
was determined in previous studies (Mehta and Champney 2002), for
experiments examining the assembly inhibition. In the absence of the antibiotics
cell growth continued exponentially (Fig 12A). Cell growth with 10μg/ml of
neomycin or paromomycin decreased the growth rate by more than 50%, with
neomycin having a greater inhibitory effect. In certain experiments, streptomycin
was used to enhance the binding of neomycin and paromomycin to ribosomal
subunits (Lando and others 1978). Streptomycin is an inhibitor of protein
synthesis, so at 2 μg/ml there was a small lag in cell growth compared to cells
grown without antibiotic (Figure 12B). Cells grown with streptomycin in
combination with neomycin or paromomycin, were still inhibited by 50%.
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Figure 12 Cell Growth of E.coli SK901 Growing in the Absence and Presence of
Neomycin, Paromomycin, and Streptomycin. A.) Cells were grown in the
absence of the antibiotic (□), or with neomycin (10µg/ml) (∆), or paromomycin
(10µg/ml) (○). B.) Cells grown with streptomycin alone at 2μg/ml (◊), or with
streptomycin and neomycin (▲), or with streptomycin and paromomycin (●), or
no antibiotics (□).

Identification of the 30S Ribosomal Assembly Intermediate
Mehta and Champney showed cells treated with neomycin and
paromomycin produced a precursor particle with a sedimentation coefficient of
21S (2002). The intent of this experiment was to determine if this precursor
particle could be successfully isolated from cells for further analysis. Sucrose
gradient profiles show 30S assembly inhibition (Figure 13) and the accumulation
of a p30S particle in cells grown with paromomycin or neomycin. Cells were
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lysed and separated under high magnesium conditions (10mM) to ensure
complete separation of the precursor from mature subunits. In the presence of
the antibiotics, immature ribosomes are unable to associate with 50S particles
and prevent 70S particle formation. When treated with antibiotics there was a
greater accumulation of RNA in the precursor region of the gradient. The
gradient profile in Figure 13B represents pooled fractions from sucrose gradient
lysates from neomycin treated cells shown in Figure 13A. Mehta and Champney
have already shown that the 30S assembly intermediate sediments in this region
of the gradient (2002,2003) and Figure 13B confirms that in the presence of
neomycin a 21S precursor particle does accumulate in this region and can be
successfully isolated. Similar results were obtained using paromomycin (data not
shown).
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Figure 13 Sucrose Gradient Profiles of E.coli SK901 Treated With Neomycin or
Paromomycin. A.) Sucrose gradient profiles of cell lysates. Cells were grown in
the absence of the antibiotic (■), or with neomycin (10μg/ml) (∆), or paromomycin
(10μg/ml) (○).The cells were lysed and layered on R buffer sucrose gradients
and 3H-uridine incorporation determined by liquid scintillation. B.) The p30Sneo
assembly intermediate (∆) collected from fractions 9-15 of the gradient from
neomycin treated cells (Figure 13A). The same fractions were collected for the
p30S particle from untreated cells (■).
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Identification of 16S RNA in the 21S Intermediate

To substantiate that the p30S assembly intermediate was indeed a
precursor to the 30S subunit, the rRNA content was examined in cells grown with
neomycin and paromomycin. RNA isolated from sucrose gradient fractions of
cell lysates treated with or without antibiotic was hybridized with a 16S DNA
probe, and the signal was negative in the precursor region for control cells and
cells treated with streptomycin (2μg/ml). While streptomycin is an inhibitor of
protein synthesis, it has no effect on assembly inhibition (Figure 14A). Relative
spot intensities of 16S rRNA hybridization of fractions from cells treated with
neomycin (Figure 14B) shows the presence 16S rRNA in the p30S and 30S
subunit regions of the gradient. Similar results were also found in cells treated
with paromomycin, but with lesser amounts of 16S hybridization to smaller RNA
fragments that sediment in fractions 1-5 of the gradient (Figure 14C).
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Figure 14 Hybridization Analysis of Sucrose Gradient Fractions From Antibiotic
Treated and Control Cells. Slot blots of 16S rRNA hybridization of RNA isolated
from sucrose gradient fractions of cells grown with or without antibiotic. A.) Cells
grown without antibiotic (■) or with streptomycin (2μg/ml) (◊). B.) Cells grown with
neomycin alone (10μg/ml) (▲), or with neomycin and streptomycin (2μg/ml) (◊).
C) Cells grown with paromomycin alone (10μg/ml) (●), or with paromomycin and
streptomycin (2μg/ml) (◊).

Northern Hybridization Analysis of 16S and Precursor RNA

Maturation of 16S rRNA is coupled with 30S subunit assembly and
unprocessed RNA are not present in a mature functional 30S subunit. However,
an accumulation of precursor rRNA occurs in cells defective in 30S or 50S
subunit assembly (Himeno and others 2004; Kaczanowska and Aulin 2005).
Therefore, gel electrophoresis was employed to examine the type of rRNA
species in the p30S intermediates isolated from drug treated cells. Total RNA
from drug treated cells was analyzed on a 1.8% agarose gel (Figure 15A). Lane
1 contains mature 16S RNA isolated from 30S subunits. Precursor RNA as well
as mature 16S RNA was identified in control cells (Lane 2). The cells were grown
at a lower than normal temperature (27°C) and because 16S maturation is
coupled with assembly, small amounts of natural precursor (p30S) are available.
A band slightly larger than 16S was identified in cells treated with neomycin and
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paromomycin (Lanes 3 and 4) corresponding to the position of 17S RNA. The
amount of 16S remained the same and treatment of cells with either antibiotic
had no effect on 23S rRNA (Lanes 2-4).
Northern hybridization was performed using probes specific for the 3' and 5'
precursor sequences of 17S rRNA to determine the effects on RNA processing.
Hybridization with the 5' probe to RNA from the gel shown in Figure 15A identified
immature RNA in both antibiotic treated and untreated cells (Figure 15B).
However, greater amounts of 17S rRNA were observed with neomycin and
paromomycin (lane 3 and 4) using the 5' probe. In contrast, 17S RNA detected
using the 3' probe was seen only in antibiotic treated cells with increased levels in
the presence of paromomycin (lane 4). The reduced amount of 16S RNA in drug
treated samples was probably a result of RNA degradation.
Densitometry measurements of the relative amounts of RNA from Northern
blots hybridized with mature and precursor 16S probes are shown in Figure 16.
The amount of 16S RNA remained the same in absence and presence of
antibiotic. In the absence of antibiotic, there was a greater amount of 5' precursor
compared to 16S RNA and 3' immature RNA in drug treated cells. However
compared to non-treated cells, treatment with neomycin caused a 2.5 fold increase
in 3' precursor and a 1.5-fold increase in 5' RNA. In the presence of paromomycin,
there was a 4.5 and 1.7 fold increase in 3' and 5' precursor RNA respectively.
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Figure 15 Identification of immature 17S rRNA of the 21S ribosomal assembly
intermediate. A.) Agarose gel of rRNA from antibiotic treated cells showing the
size of rRNA present in cells treated with or without antibiotic. Total RNA (5μg)
was electrophoresed on a 1.8% MOPS-formaldehyde agarose gel for 2.5 hrs at
50 volts. 16S rRNA was identified in untreated and drug treated cells (lanes 2-4)
as compared to mature 16S RNA isolated from 30S subunits (lane 1). The band
above the 16S RNA represents the position of 17S RNA (lane 3 and 4). B.) A
Northern blot of RNA from the agarose gel in 15A after hybridization with 5' and
3' probes specific for 17S RNA and an internal 16S probe.

54

1.25

A
Fold Increase

1

16S MEAN FOLD

0.75
0.5
0.25
0
16S

ND

NEOMYCIN

PAROMOMYCIN

20

B

fold increase5'

Fold Increase

15
10
5
0
16S

ND

NEOMYCIN

PAROMOMYCIN

8
Fold Increase

C.
mean fold

6
4
2
0
16S

ND

NEOMYCIN

PAROMOMYCIN

Figure 16 Relative Amounts of 17S rRNA from Cells Treated With Neomycin and
Paromomycin. The relative intensity from integration of Northern blots hybridized
with mature and precursor 16S probes are shown as a fold increase. The
amount of 16S rRNA was set as one. A.) 16S probe B.) 5' precursor probe C.) 3'
precursor probe. Error bars are SEM of three determinations.
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Analysis of the In Vivo 21S Intermediate Ribosomal Protein Composition
Sequential addition of 30S ribosomal proteins in vitro revealed that a
subset of proteins was critical to initiate folding of 16S rRNA. The organization
and presence of these proteins alters the conformational state of the ribosomal
complex. In addition, the alternate and transient conformations that are seen in
vitro are likely to occur during assembly in vivo (Culver 2003). Characterizing the
RNA structure and protein composition is critical for understanding the
conformation of the p30S intermediate from drug treated cells. Two-dimensional
gel electrophoresis was employed to identify which proteins were present in the
p30S intermediate from drug treated cells. The p30S region was isolated from
sucrose gradients of cells grown with 35S-methionine treated with or without
antibiotic as described in Figure 13. Proteins from p30S, p30Sneo, and p30Sparomo
were isolated and resolved on an 18% polyacrylamide two-dimension gel (Figure
17). Liquid scintillation counting of excised protein spots indicated an increase in
radioactivity of fractions 9-16 pooled from the precursor region of sucrose
gradients treated with antibiotic as compared to untreated samples. In the
absence of antibiotic, cells are naturally producing some precursor; therefore,
proteins present in these cells served as the background. For antibiotic treated
cells, 35S-methionine incorporation into proteins identified in this region equal to
or above non-drug samples were considered present. Of the 21 30S ribosomal
proteins, 11 were present in the precursor particle from cells treated with

56

neomycin (p30Sneo) as shown by the increase in 35S-methione incorporation
compared to cells without antibiotic (Figure 18A). Similar results were found in
cells treated with paromomycin where 10 proteins were present. A comparison of
the p30Sneo and p30Sparomo protein content with the p30S intermediate (Nomura
1973), and in vitro intermediate RI (Held 1974) is shown in Table 1.
The protein content of the p30Sneo and p30Sparomo was similar with the
exception of S4 which was absent in the p30Sparomo intermediate. There was a
greater difference between the neomycin and paromomycin intermediate
compared to the RI particle. These differences may reflect the use of mature
RNA in reconstitution experiments versus precursor RNA in cells.
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Figure 17 2D Gel Electrophoresis Pattern of 30S Ribosomal Proteins. An 18%
polyacrylamide gel of ribosomal proteins from the p30S intermediate. The protein
pattern was also the same for the p30Sneo and p30Sparomo intermediates. Prior to
protein extraction, each 35S-methionine labeled intermediate particle was mixed
with 100 μg of non radio labeled 30S proteins for spot detection. Electrophoresis in
the first dimension was 5 hrs at 100V and the second dimension 18hrs, followed by
Comassie Blue staining. Each spot was excised from the gel, digested with 30%
hydrogen peroxide and the radioactivity in the proteins were detected by liquid
scintillation counting.
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Figure 18 Radio labeled Ribosomal Proteins Present in the Assembly
Intermediate from Antibiotic Treated Cells. A.) Ribosomal proteins present in the
precursor particle from cells treated with neomycin (10μg/ml) or B.) paromomycin
(10μg/ml). Solid grey bars represent the threshold level of radioactivity of proteins
isolated from the precursor from cells without antibiotic treatment (same in A and
B). A representative threshold level for each protein is represented by the dashed
line. However, each ribosomal protein in the p30Sneo and p30Sparomo was
compared to the corresponding protein from the p30S region of untreated cells.
The amount of radioactivity is represented as the percent of the total radioactivity
in each gel and mean of three experiments. The differences in methionine
content in the ribosomal proteins were normalized by a procedure described by
Giri and others by dividing the radioactivity present in each protein by the number
of methionine residues for the protein (Giri and others 1984). The proteins with

59

an asterisk were considered to be absent in the antibiotic treated intermediates.
Error bars represent the SEM of the mean of 3 gels.

Table 1 30S Ribosomal Proteins Present In The Precursor Region of Sucrose
Gradients From Antibiotic Treated Cells.
Proteins that were judged to be present in the isolated 30S precursor labeled
with methionine are indicated with a (+). The third column represents ribosomal
proteins present in the natural 21S assembly intermediate (p30S) (Nomura 1973)
and the fourth column the in vitro 21S reconstitution intermediate (RI) (Held
1974; Culver 2005).
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Antibiotic Binding to the In Vivo Assembly Intermediate
Hybridization experiments (Figure 14B-C) identified 16S rRNA in the p30S
ribosomal intermediates in cells grown with neomycin and paromomycin. Other
analysis have shown that aminoglycosides can bind to 16S rRNA in the absence
of ribosomal proteins. It is therefore likely that the p30S intermediate particle that
contains a partial protein content is capable of binding antibiotic as well. In vivo
and in vitro binding assays were conducted to determine if the precursor particle
was capable of binding radio labeled antibiotics. Streptomycin was added to
enhance neomycin and paromomycin binding (Lando and others 1976) and the
data revealed that binding of paromomycin increased by 60 % (Figure 19). Figure
20 shows sucrose gradient profiles from cells grown with radio labeled
antibiotics. 3H-antibiotic binding to rRNA was seen in the p30S region of the
gradient. As expected, the sucrose gradient profile also shows specific binding
to the 30S subunit and this was comparable to the binding shown for neomycin to
the 21S intermediate (Figure 20A). Paromomycin had a less inhibitory effect on
cell growth and decreased binding to the 21S particle is evident in Figure 20B.
Neomycin and paromomycin binding was observed to 50S subunits as well
(Figure 20 A-B).
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Figure 19 Streptomycin Enhances Paromomycin Binding to the In Vivo 30S
Assembly Intermediate. Cells were grown in the presence of 3H-paromomycin
(4μg/ml) (●) or with streptomycin (♦) (2μg/ml) and 3H-paromomycin (4μg/ml).
Cell lysates were separated on 5-20% R buffer sucrose gradients. Without
streptomycin maximum binding occurred at 300 cpm (●) (fraction 13) and with
streptomycin at 1000 cpm (♦) (fraction 13).
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Figure 20 Aminoglycoside Binding to the In Vivo 30S Assembly Intermediate.
Cells were grown in the presence of A.) 3H-neomycin (◊) or B.)3H-paromomycin
(○). Non radio-labeled neomycin or paromomycin were added at 10µg/ml and
streptomycin at 2µg/ml.

Filter binding assays were performed to study neomycin and paromomycin
binding in vitro. Isolated p30S from pooled fractions (9-15) of sucrose gradients
(Figure 13 A-B) were dialyzed against R buffer to remove bound antibiotic. Figure
21 shows an increased concentration dependent binding of 3H-paromomycin to
50S, 30S, and p30S particles. The amount of binding correlates with the
difference in size of each particle.

Although binding to 50S particles was not

expected, similar results were seen with paromomycin binding to streptomycin
sensitive ribosomes (Lando and others 1978) and with neomycin (Dahlberg
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1978; Misumi 1980). Particle binding did not reach saturation so an association
constant could not be determined. Nevertheless, these results do show that the
isolated p30S particle is capable of binding antibiotic with a similar affinity as 30S
subunits.
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Figure 21 In Vitro Binding Of 3H-Paromomycin to E. coli Ribosomal Subunits and
the 21S Precursor Particle. 3H-paromomycin (Moravek Biochemicals) was used.
5 pmoles of 30S (□) or 50S (∆) ribosomal subunits or p30S (○) precursor were
used. The p30S particle was isolated from cells as described in Figure 13A-B.
Results are shown as SEM three determinations.
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Inhibition of 30S Assembly In Vitro
Ribosomal reconstitution allows an in depth analysis of the functional roles
of individual components in both subunit assembly and ribosome function.
Studying subunit assembly in vivo is often difficult because genetic mutations are
frequently lethal. Reconstitution can be performed using modified or mutated
rRNA transcripts and recombinant proteins to examine assembly in vivo (Culver
2003). Therefore, 30S assembly inhibition by neomycin and paromomycin was
examined using ribosomal reconstitution. Figure 22A represents the
sedimentation profiles of 16S rRNA, 30S, and 50S subunits isolated from cells
labeled with 3H-uridine. The 21S particle (RI) was formed by reconstitution of 16S
rRNA and 30S ribosomal proteins at 4°C. The fraction number corresponding to
the peak for each particle was plotted versus its sedimentation coefficient and the
standard in shown in Figure 22B. The sedimentation values of the intermediates
produced in later reconstitution experiments were determined using the equation
of the slope in Figure 22B.
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Figure 22 Sucrose Gradient Profiles and Standard Curve for Sedimentation
Coefficients for Ribosomal Subunits and 16S rRNA. A.) Sucrose gradient
profiles for 3H-uridine labeled 16S rRNA (●), the 21S reconstitution intermediate
(RI) (▲), 30S subunit (■), 50S subunit (●). The subunits and rRNA were isolated
from cells and centrifuged on 5-20% S buffer sucrose gradients. B.) A standard
curve showing the linearity of the sucrose gradient and sedimentation of each
particle. The peak fraction from the sucrose gradient in 23A is plotted on the Xaxis versus the S value of the particle (Y-axis).

16S rRNA isolated from 3H-uridine labeled cells was reconstituted with a
four fold molar excess of 30S ribosomal proteins. The sucrose gradient profile in
Figure 23A shows complete assembly of a 30S subunit from reconstitution
performed at 40°C. The activity of the reconstituted subunits were not examined,
but others have shown that reconstitution performed with the conditions
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described in this study are capable of poly phenylalanine synthesis and
reassociation with 50S subunits (Spedding 1990).
Traub and others have shown that reconstitution at 4°C produces a
particle, RI, with a sedimentation coefficient of 21S (1971). These conditions
were used to produce the RI particle in Figure 23A, which later was compared to
the intermediates produced in the presence of drug. The intermediate formed at
4°C represented the maximum amount of 21S formation under the above
conditions.
Figure 23B shows reconstitution of 30S subunits at 40°C with a 10,100,
and 1000-fold excess of neomycin or paromomycin. Increasing concentrations of
the antibiotic inhibited the reconstitution of the RNA into a 30S subunit. The
intermediate produced by neomycin was RIneo with a sedimentation coefficient of
21S. Reconstitution with 0.4μM neomycin did not produce an intermediate
particle suggesting that the RNA and proteins were not able to assemble under
these conditions. In contrast, reconstitution with paromomycin at the same
concentration resulted in a 21S particle (RIparomo). This result also occurred with
0.2 and 0.04μM of paromomycin.
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Figure 23 Inhibition of 30S Assembly In Vitro by Aminoglycosides. A.) 30S
reconstitution in the absence of antibiotic at 40°C (□). 0.5 A260 units of 3H-16S
rRNA and 2.0 A260 of total 30S ribosomal proteins were used. Reconstitution
performed under the same conditions except at 4°C produced a 21S particle (RI)
(○). The reconstituted particles were layered on 5-20% sucrose gradients in buffer
# 7 and the profiles were determined by liquid scintillation counting following
centrifugation. B.) 30S reconstitution at 40°C was performed as described in A.
but in the presence of neomycin, 0.04μM (∆), 0.2 μM (▲), and 0.4 μM (□) C.) 30S
reconstitution at 40°C with 0.04μM (○), 0.2 μM (●), and 0.4 μM (□) of
paromomycin.
Increasing concentration of neomycin and paromomycin resulted in a
decrease in 30S subunit formation (Figure 24), suggesting that smaller amounts
of RNA were able to associate into a complete particle. On the other hand, the
increased amount of RIneo or RIparomo at the lower concentration of drug shows
that a greater amount of RNA was capable of reconstituting and possibly
proceeding to 30S assembly. While more precursor accumulation is seen in
vivo, reconstitution examines RNA folding and protein association, and the
factors that would limit the formation of 30S assembly.
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Figure 24 The Percent of 30S Formation with Increasing Concentration of
Neomycin or Paromomycin. The amount of 30S formation is represented as a
percent of the sum of radioactivity in the RIneo and RIparomo particles (fractions 916) and the total amount of RNA from each sucrose gradient in Figure 24. The
maximum amount of precursor formed without drug is RI as shown in Figure 24A,
neomycin (∆), and paromomycin (○). Data are shown as the SEM and the mean
of three experiments.
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CHAPTER 4
DISCUSSION
This work supports earlier findings that showed a number of antibiotics that
inhibit translation in cells also prevent ribosomal subunit assembly. Previously,
erythromycin was found to inhibit ribosome assembly in E.coli in a fashion similar
to the present studies using neomycin and paromomycin. A 50S precursor
particle sedimenting in the 30S region of sucrose gradients from erythromycin
treated cells contained 23S rRNA and bound antibiotic both in vivo and in vitro on
the 50S subunit. In addition, the 50S precursor contained 18 of the 34 ribosomal
proteins (Usary and Champney 2001). The translational inhibitors neomycin and
paromomycin prevent 30S subunit assembly in a similar manner to what was
observed for 50S assembly.
The intent of this work was to explore the features 30S assembly inhibition
by these antibiotics. The in vivo precursor particle that accumulated in the
presence of neomycin and paromomycin was characterized by identifying the
protein composition, rRNA content, and antibiotic binding. Both antibiotics were
capable of binding to the p30S assembly intermediate with neomycin having a
greater affinity. Hybridization analysis confirmed that the 21S particle that bound
both antibiotics was composed of both 16S and precursor 17S rRNA, showing
that it was truly a stalled intermediate of the 30S subunit. Furthermore, the
ribosomal protein composition of this intermediate was identified.
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Neomycin and Paromomycin Binding to the 30S Assembly Intermediate
Binding assays revealed that the p30S intermediate and mature 30S
subunits bound neomycin and paromomycin (Figures 19-21). This result was
expected because that paromomycin binds to specific nucleotides of 16S rRNA
in vitro, and that this interaction is important for antibiotic activity (Fourmy and
others 1996,1998; Recht and others 1999). Furthermore, paromomycin binding
induced a conformational change in the A site stabilizing RNA-RNA interactions
(Fourmy 1999, Barbieri 2007). Footprinting analysis also revealed considerable
protection of nucleotides in the A site when neomycin and paromomycin were
bound to protein-free 16S rRNA (Purhoit and Stern 1994). These observations
suggest possible interactions of the antibiotics with RNA before the native 30S
conformation is stabilized (Fourmy and others 1996, 1998). Such findings
support the hypothesis that the antibiotics inhibit assembly by interacting with
16S RNA as the subunit forms.
In the binding studies using radio labeled antibiotics, neomycin bound to
particles with a greater affinity. The total amount of radioactivity in the p30S
region of the gradient increased by 25% for cells treated with 3H-neomycin
(Figure 20) compared to 3H-paromomycin. Initial studies on assembly inhibition
had shown that in both S.aureus and E.coli, there was a similar reduction in
growth rate and 30S formation with neomycin than with paromomycin (Mehta and
Champney 2002, 2003). The two antibiotics are similar in structure, but the
difference in one functional group can affect binding to RNA. Specificity of
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aminoglycosides for the A site is a result of eight direct contacts between the
conserved neamine core, but each antibiotic can make additional contacts within
the A site, increasing specificity. Crystal structures of aminoglycosides
complexed with A site RNA revealed that the number of antibiotic molecules
occupying the A site were dependent on the number of rings and positive
charges (Francois and others 2005). Kinetic analysis from several other groups
also revealed that neomycin binds with a greater affinity to the A site than does
paromomycin and other aminoglycosides (Benveniste and Davies 1973; Francois
and others 2005).
One possible explanation for the increased binding of neomycin over
paromomycin may be due to the amino group in neomycin, which increases the
net charge to +6. This may facilitate an additional contact with the negatively
charged RNA, relative to a hydroxyl group at C'6 of ring I in paromomycin. While
this may contribute to antibiotic binding, a more plausible explanation could
involve the position of the additional positive charge. Ring I establishes initial
antibiotic and RNA contacts by forming a pseudo base pair with A1408. This
allows the neamine core to stack above base pairs A1409:U1491 and
A1406:U1495. These specific contacts mediate the “flipping out” of adenines
1492 and 1493, the structural rearrangement that induces misreading (Ogle and
others 2002, 2003; Westhof and Vicens 2003).
Studies have shown that mutations in nucleotides of the A site that bind
aminoglycosides distinctly affect those with an OH group versus NH3 (Pfister and
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others 2005). Mutations of A1409 and A1491 in 16S RNA revealed that
aminoglycosides with an OH at position C'6 developed increased resistance and
interrupted stacking with A1409:A1491. Although neomycin and paromomycin
were able to base pair with A1408, the NH3+ group was able to compensate for
the stacking disruption. Moreover, of the aminoglycosides examined, neomycin
exhibited the greatest affinity for the mutant ribosomes. Others have suggested
that the three additional hydrogen bonds formed with neomycin, as well as the
energy difference resulting from the charged NH3+ hydrogen bond, contribute to
this association (Pilch and others 2003).
Binding to the 50S Subunit
Many of these features might explain neomycin and paromomycin binding
to the 50S subunit (Figure 20-21). Although the literature supports that neomycin
and paromomycin are specific for the 30S subunit, binding was observed to the
large subunit both in vivo and in vitro. Studies by Lando and others described
similar binding of paromomycin to 50S subunits in vitro (1978). Also antibiotic
competition assays between kanamycin and neomycin resulted in reduced
kanamycin binding to 50S and 30S subunits by 90%. This was not observed with
streptomycin, which is not specific for the ribosomal A site (Misumi and others
1978). Electrophoretic mobility shift assays of ribosome cell lysates treated with
neomycin showed an increased mobility of both 30S and 50S particles,
suggesting the drug was capable of binding to and causing structural
arrangements of both particles (Dahlberg and others 1977).
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These 50S interactions are not surprising considering the promiscuous
nature of these antibiotics. Aminoglycosides are capable of binding to several
RNA motifs such as RNA aptamers, the HIV Rev Response element, and group I
introns (Ashen and others 1991, Zapp and others 1993). Their flexibility around
the glycosidic bonds and positive charge makes them suitable candidates for
interaction with a myriad of RNA molecules (Tor 2006). Thus, these
investigations highlight a new exploratory feature for these drugs. However,
these data are not sufficient to allow any specific conclusions, but it must be
noted that they have no specific effect on 50S assembly and do not stimulate
turnover of 23S RNA (Figure 15) (Mehta and Champney 2002, 2003).
Ribosomal RNA Analysis
Analysis of rRNA from the stalled intermediates in cells treated with
neomycin and paromomycin revealed an accumulation of 16S rRNA in the 21S
precursor region of the gradient (Figure 14B-C). This further substantiates
findings that the antibiotic binds specifically to the 16S rRNA of the assembly
intermediate. The presence of precursor RNA in this particle indicates that
neomycin and paromomycin are indeed inhibiting the maturation of 30S subunits.
Similar results have been seen in cells defective in a number of ribosomal
assembly factors such as chaperones and GTPases (Charollias 2003). A
temperature sensitive mutation of the heat shock protein DnaK in E.coli caused
defects in the later stages of ribosome biogenesis. This was evident by an
accumulation of unprocessed forms of 16S and 23S rRNA from 21S, 32S, and
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45S ribosomal intermediates. Era, a GTPase binding protein essential for cell
growth in E.coli, binds to 30S subunits as well as 16S rRNA in vitro. Depletion
of the protein resulted in an accumulation of precursor 16S rRNA and a decrease
in 70S ribosome formation (Sayed and others 1999). Cells containing mutations
in several other GTPases, such as RsgA and YrdC, also resulted in an
accumulation of immature 16S rRNA (Himeno and others 2004; Kaczanowska
and Aulin 2005). Altogether, these ribosomal factors assist in the RNA
conformational rearrangements necessary for subunit formation. In the absence
of these factors, assembly is incomplete as is evident by 21S precursor and
immature rRNA accumulation. Interestingly these results show that
aminoglycosides produce similar assembly defects.
Northern hybridization analysis revealed differences in RNA processing
in the presence of both antibiotics. Antibiotic treatment had a greater effect on
maturation of the 5' end (Figure 15-16). This was surprising considering the
polarity of transcription. The differences in 5' and 3' precursor observed in these
studies may reflect the importance of the 5' precursor during assembly. Beascon
and Wagner revealed that 5' leader sequences are critical during the early stages
of assembly. Their kinetic analysis showed that the leader sequences formed
transient interactions with the 5' domain of 16S RNA, and deletions in this region
resulted in major assembly defects. They concluded that the 5' leader was
needed to prevent premature folding of 16S RNA during assembly (1999).
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Ribonuclease III was shown to cleave RNA sequences at the 5' end of
17S rRNA but only after the addition of ribosomal proteins, suggesting that the
final maturation of 16S rRNA depends on the formation of the ribonulceoprotein
complex (Srivastava 1990). In addition, formation of the RI intermediate largely
consists of arrangements in the 5' and central domains therefore these regions
are probably protected by RNA-RNA or protein interactions. On the other hand,
the 3' domain consisting of minor RNA conformations is readily accessible and is
sufficient for RNase cleavage.
This, however, does not sufficiently explain RNA degradation observed
in the presence of both antibiotics. While the 3' end is more accessible as
assembly proceeds, degradation of the 3' end is probable in abnormal cells given
that exonuclease activity begins at the 3' end. Thus, greater amounts of 5'
precursor would be present compared to 3' precursor RNA.
The difference in amounts of 5' or 3' precursor may also reflect the affinity
or neomycin and paromomycin for the p30S intermediate. Treatment with
paromomycin resulted in larger amounts of 3' precursor (Figure 16). The
decreased affinity of paromomycin for the p30S intermediate would result in
faster dissociation from the particle making it less susceptible to RNA
degradation. Exploration of this claim requires further examination of RNA
processing. Nevertheless, these results support the idea that aminoglycosides
perturb assembly by affecting RNA conformational changes needed to form
mature functional 30S subunits.
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Ribosomal Protein Analysis
The precursor particle from antibiotic treated cells contained a different
protein composition compared with the natural 21S (p30S) particle (Nomura
1973). The dissimilarity could indicate how these antibiotics affect protein-RNA
conformations during assembly. In the p30S particle tertiary proteins S2, S3,
S10, S14, and S21 are missing in addition to three secondary proteins. In
contrast, the paromomycin stalled intermediate included S3, S10, and S14, and
neomycin produced an intermediate with tertiary proteins S10 and S14 (Figure
25). In vitro association of these proteins can only occur following an energy
dependent rearrangement of the RNA in the precursor from 21S to 26S. This
transition creates functional binding sites for the tertiary proteins as well as the
30S subunit. The presence of S3, S10, and S14 in the antibiotic intermediate
could suggest that some structural features akin to the 30S may be present in the
21S particle. In addition, protein binding of S3, S10, and S14 is interdependent
and forms a hydrophobic core within the RNA, a feature that could stabilize
antibiotic interactions.
Analysis of 21S intermediates from chaperone deficient cells also revealed
differences in protein composition. Ribosomal proteins S1, S14, and S21 were
absent in 21S particles isolated from cells missing ObgE (Sato and others 2005).
In the absence of chaperone DnaK, 21S intermediates did not contain S3, S10,
S14, S21, S2, and S5 (El Hage and Alix 2004). These variations indicate that not
all p30S precursors are identical in spite of having the same S value, and that
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they differ in protein content, indicating flexibility in the formation of 21S
intermediates. In addition, multiple pathways may exist to form a functional 30S
subunit and initial stages may allow flexibility in the order of protein folding or
association. However, the 21S and 26S particles have been identified to be the
most critical particles (reviewed in Culver 2003).
The absence of S8 in the precursors resulting from antibiotic treatment
further supports the hypothesis that different structural arrangements occur
during assembly. A primary binding protein, S8 stabilizes the central domain and
provides binding sites for S6 and S18. Ribosomal protein S8 is also required for
subsequent binding of S5 and S12, which are absent in the p30Sneo and
p30Sparomo intermediates (Figure 25). The absence of this protein suggests that
neomycin and paromomycin may indirectly affect formation of the central domain
or that an alternate mode for its formation exists. In the absence of primary
protein S15, 30S subunits were able to assemble in vivo. However, under
suboptimal conditions or in vitro, subunits failed to assemble. Chemical probing
and primer extension of mutant subunits revealed a similar protection pattern
with wild type cells suggesting that the structure was the same. S15 forms
binding sites for secondary proteins, but Orr and others showed that Mg2+ can
cause similar changes in RNA structure to facilitate S15 binding (1998).
Aminoglycoside binding rearranges the massive 30S structure, moving its head
(5' domain) towards its body (3' domain), so it is not likely that compensatory
rearrangements can occur during assembly. This may actually allow the drug to
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be more accessible to the RNA during assembly, potentially locking the RNA in a
conformation that precludes the addition of other proteins.

Figure 25 Ribosomal Proteins Missing in the p30S Particles from Antibiotic
Treated Cells. Proteins circled in black were absent in the p30neo and
p30Sparomo assembly intermediates. The absence of proteins circled in yellow
was dependent on the antibiotic used (Table 1).
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Structural Comparison of Assembly Intermediates
The results of this work have provided insight on the features of 30S
ribosomal subunit assembly inhibition by neomycin and paromomycin in
identifying the ribosomal RNA and protein content of the precursor particle.

The

data show that neomycin and paromomycin can impair this process producing a
21S intermediate (Figure 9). However, the extent of assembly inhibition is equal
to the extent of protein synthesis inhibition (Champney 2003), implying a
heterogeneous population may exist.
Structural data show that in normal cells that RNA undergoes successive
changes in structure at each intermediate step. More than 50% of the changes
observed during the 16S to 21S transition occur in the 5' and central domains.
While assembly proceeds with transcriptional polarity, minor changes in the 3'
domain take place in this early stage. A continuation of protection in certain
domains or an incremental change in reactivity of 11 nucleotides during all three
stages represents the dynamics of this concerted process (Holmes and Culver
2005).
The data presented here show that these assembly pathways are not
congruent and that other features may exist for antibiotic binding to the stalled
intermediate. In normal assembly, the decoding center forms subsequent to the
21S to 26S transition. Included in this stage is rearrangement of the 530-stem
loop that forms the central psuedoknot connecting the head, body, and platform.
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The addition of tertiary proteins in the last assembly step (26S to 30S) results in
accommodation of sites formed in the previous step and formation of the
decoding pocket. In addition, protections of nucleotides C1399-G1504, which
are adjacent to the decoding region, occur during this stage (Holmes and Culver
2004). We have identified an intermediate particle which includes three of the
tertiary proteins responsible for these late assembly transitions but sediments at
21S. These differences may enhance drug binding during assembly and indicate
important features of a novel target for aminoglycosides in cells.
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